Skip to main content

Table 1 Characteristics of the study sample

From: Electroacupuncture analgesia is associated with increased serum brain-derived neurotrophic factor in chronic tension-type headache: a randomized, sham controlled, crossover trial

 

Sequence phase

 
 

Electroacupuncture first (n = 17)

Sham first (n = 17)

P

Age (years)

39.11 (±10.5)

41.44 (±10.5)

0.36

Formal education (years of study)

14.44 (±3.9)

14.21 (±2.9)

0.85

Clinical comorbidity

4 (22%)

2 (12.5%)

0.66

Smoking

1 (5.5%)

0

1.00

Pain on the 10-cm VAS

6.02 (±1.5)

6.50 (±1.4)

0.28

HIT-6

63.00 (±6.4)

61.44 (±5.2)

0.44

HDRS

7.83 (±3.8)

6.69 (±2.8)

0.33

Psychiatric disease

6 (33.3%)

4 (25%)

0.59

B-PCS

32.17 (±13.5)

27.81 (±15.1)

0.38

Helplessness

14.17 (±6.9)

12.25 (±7.1)

0.43

Magnification

7.11 (±3.4)

5.69 (±3.8)

0.26

Rumination

10.78 (±3.7)

9.88 (±5,03)

0.55

Serum BDNF (ng/mL)

42.67 (±34.6)

43.2 (±21.4)

0.95

Daily use of analgesics (Yes/No)

14/3

15/2

0.66

Dorflex®

10

12

 

NSAID

4

2

 

Acetaminophen

4

2

0.81

  1. Values are given as the mean (±SD) or as frequency (percentage of cases) (n = 34).
  2. Abbreviations:VAS Visual analog scale, HIT-6 headache impact test, HDRS Hamilton depression rating scale, BP-PCS Brazilian Portuguese pain catastrophizing scale, B-PCS pain catastrophizing scale validated for the Brazilian population, BDNF brain-derived neurotrophic factor, NSAID non-steroidal anti-inflammatory drug, Dorflex® (Sanofi Aventis, Sao Paulo, Brazil; 35 mg Orfenadrine citrate combined with 300 mg Metamizol (Dypirone) and 50 mg caffeine)).